As a result of exercise data and bleeding frequency study after administration of type A hemophilia treatment, international academic journals are published...JW Pharmaceutical Hemlibra has only two cases of exercise-related bleeding.
Aug 11, 2025
Recently, various exercise data and research results of patients taking type A hemophilia drugs 'Hemophilia' were published in the international academic journal 'Hemophilia' that demonstrated the effectiveness of preventing bleeding.
A research team led by Kagehiro Amano of the Department of Diagnostic and Testing Medicine at Tokyo Medical University conducted a study on 129 non-antibody type A hemophilia patients with an average age of 29.7 from January 2019 to October 2021. The research team evaluated patients' exercise and intensity, bleeding, and safety after administration of JW Pharmaceutical's hemibra through the electronic patient reporting application 'ePRO' and Wearable Activity Tracker.
Seventy-three of the patients taking hemibra recorded the exercise performed for eight days at week 5, 25, 49, 73, and 97 in ePRO. A total of 968 exercises were reported during the period, of which 58 were exercises with a high risk of bleeding, including soccer, marathon and weightlifting.
Among the aggregated exercises, walking was the most common with 374 cases (38.6%), followed by 112 cycles (11.6%) and 84 full-body stretches (8.7%). Metabolic equivalents (METs), which numerically represent exercise intensity, recorded an average median of 2.39 MET for all exercises, and an average median of 4.30 MET for the maximum MET recorded during exercise. The median daily average exercise time was 30 minutes, similar to the guidelines recommended for the general public (60 minutes per day, 3 MET levels).
The median annual bleeding rate (ABR) of 129 patients was 0.5. There were only two cases of exercise-related bleeding, traumatic bleeding caused by being hit by a ball while playing basketball and bleeding during fishing. No adverse drug reactions related to hemlibra were found.
The researchers found that type A hemophilia patients who received hemlibra could do a variety of exercises without worrying about bleedingThe study has demonstrated that you can safely enjoy the health benefits of exercise.
A JW Pharmaceutical official said "In that the exercise performed by patients was similar to the recommended level for the general population, we expect Hemlibra to allow us to enjoy the same activities as the general population without increasing the risk of bleeding."
Meanwhile, according to JW Pharmaceutical, Hemlibra is an innovative new drug that mimics the blood coagulation factor 8 that is insufficient in the body of hemophilia patients. It is the only type A hemophilia treatment that can be used by both antibody and non-antibody patients who have resistance to conventional treatments (factor 8 drugs). There is also a characteristic that the preventive effect continues with subcutaneous injections up to once a four-week period. In May 2023, health insurance coverage was expanded to non-antibody severe type A hemophilia patients over the age of 1.
A research team led by Kagehiro Amano of the Department of Diagnostic and Testing Medicine at Tokyo Medical University conducted a study on 129 non-antibody type A hemophilia patients with an average age of 29.7 from January 2019 to October 2021. The research team evaluated patients' exercise and intensity, bleeding, and safety after administration of JW Pharmaceutical's hemibra through the electronic patient reporting application 'ePRO' and Wearable Activity Tracker.
Seventy-three of the patients taking hemibra recorded the exercise performed for eight days at week 5, 25, 49, 73, and 97 in ePRO. A total of 968 exercises were reported during the period, of which 58 were exercises with a high risk of bleeding, including soccer, marathon and weightlifting.
Among the aggregated exercises, walking was the most common with 374 cases (38.6%), followed by 112 cycles (11.6%) and 84 full-body stretches (8.7%). Metabolic equivalents (METs), which numerically represent exercise intensity, recorded an average median of 2.39 MET for all exercises, and an average median of 4.30 MET for the maximum MET recorded during exercise. The median daily average exercise time was 30 minutes, similar to the guidelines recommended for the general public (60 minutes per day, 3 MET levels).
The median annual bleeding rate (ABR) of 129 patients was 0.5. There were only two cases of exercise-related bleeding, traumatic bleeding caused by being hit by a ball while playing basketball and bleeding during fishing. No adverse drug reactions related to hemlibra were found.
The researchers found that type A hemophilia patients who received hemlibra could do a variety of exercises without worrying about bleedingThe study has demonstrated that you can safely enjoy the health benefits of exercise.
A JW Pharmaceutical official said "In that the exercise performed by patients was similar to the recommended level for the general population, we expect Hemlibra to allow us to enjoy the same activities as the general population without increasing the risk of bleeding."
|
This article was translated by Naver AI translator.
